Endothelin receptor antagonist (ETRA) bosentan (B) in patients with severe pulmonary hypertension (PH) associated with pulmonary disease Source: Annual Congress 2010 - Pulmonary circulation II Year: 2010
Chemokine (C-C motif) ligand (CCL)-2 regulation by IL-13 in pulmonary arterial hypertension (PAH) Source: Eur Respir J 2007; 30: Suppl. 51, 55s Year: 2007
LSC Abstract – Toll-like receptor 4 (TLR4) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF pathogenesis Year: 2015
Longterm treatment effects of pulmonary hypertantion (PH) in idiopathic pulmonary fibrosis (IPF) patients by endothelin receptor blockade (Bosentan) Source: Eur Respir J 2007; 30: Suppl. 51, 120s Year: 2007
Enhanced expression of IL-18 receptor but not soluble form of IL18R in chronic obstructive pulmonary disease (COPD) Source: Annual Congress 2011 - COPD: clinical studies and animal cell models Year: 2011
Idiopathic pulmonary fibrosis fibroblasts migrate and proliferate to CC chemokine ligand 21 Source: Eur Respir J 2007; 29: 1082-1093 Year: 2007
Monocyte chemotactic protein-1 (MCP-1) synthesis and function in pulmonary artery smooth muscle cells (PA-SMCs) from patients with idiopathic pulmonary hypertension (IPH) Source: Eur Respir J 2004; 24: Suppl. 48, 436s Year: 2004
Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment Source: Eur Respir J 2011; 38: 851-860 Year: 2011
A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease Source: Eur Respir J 2012; 39: 1415-1424 Year: 2012
The CXCL12/SDF-1, CXCR4, CXCR7 axis in experimental hypoxic pulmonary hypertension Source: Annual Congress 2009 - Pathobiology of pulmonary hypertension Year: 2009
The interleukin 13 receptor system is altered in pulmonary arterial hypertension Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006
Neutrophil chemokine receptor (CXCR1 and 2) gene expression and biopsy neutrophilia in severe exacerbations of chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2001; 18: Suppl. 33, 501s Year: 2001
Enhanced expression of proinflammatory cytokine (IL-18) and its receptor in patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2006; 28: Suppl. 50, 551s Year: 2006
Upregulation of interleukin 13 receptor alpha 2 (IL-13RA2) expression in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 267s Year: 2005
Effects of endothelin receptor antagonist (ERA) bosentan on myocardial glucose metabolism in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2017 – PAH and CTEPH Year: 2017
A possible role for toll-like receptor (TLR) 5 in fibrotic pulmonary sarcoidosis Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008
Over expression of endothelin-1 (ET-1) in lung fibroblasts (LFb) from patients with pulmonary arterial hypertension (PAH), evidence for loss of inhibitory control Source: International Congress 2016 – New findings in mucosal immunology Year: 2016
CCR5 expression and CC chemokine levels in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 25: 701-707 Year: 2005
Roundabout (Robo) receptors on pulmonary artery endothelial cells: Implications for pulmonary arterial hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016
Arterial concentration of macrophage migration inhibitory factor (MIF) increases with exercise in patients with pulmonary hypertension (PH) Source: Annual Congress 2010 - Pathobiology of pulmonary hypertension Year: 2010